Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN

Aegis Wealth Management LLC acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the second quarter, according to its most recent filing with the SEC. The fund acquired 150,030 shares of the company's stock, valued at approximately $3,332,000. Dyne Therapeutics makes up 1.6% of Aegis Wealth Management LLC's holdings, making the stock its 9th largest holding. Aegis Wealth Management LLC owned approximately 0.08% of Dyne Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Hilton Head Capital Partners LLC bought a new position in Dyne Therapeutics in the 1st quarter valued at $26,000. Strs Ohio bought a new stake in Dyne Therapeutics during the fourth quarter valued at $51,000. Aster Capital Management DIFC Ltd bought a new stake in Dyne Therapeutics during the fourth quarter valued at $84,000. Steward Partners Investment Advisory LLC grew its position in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock worth $95,000 after buying an additional 2,465 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company's stock worth $100,000 after buying an additional 7,697 shares in the last quarter. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Trading Up 1.8%

Dyne Therapeutics stock opened at $26.15 on Tuesday. Dyne Therapeutics, Inc. has a 12 month low of $11.65 and a 12 month high of $27.31. The company has a market capitalization of $4.88 billion, a price-to-earnings ratio of -7.85 and a beta of 1.07. The business's fifty day simple moving average is $23.02 and its two-hundred day simple moving average is $19.55. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33). As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -3.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jason P. Rhodes sold 2,160,516 shares of the firm's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares of the company's stock, valued at $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the firm's stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the sale, the chief financial officer directly owned 121,563 shares in the company, valued at approximately $2,476,238.31. This trade represents a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders bought 9,000 shares of company stock valued at $156,800 and sold 4,139,196 shares valued at $99,449,852. 9.46% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on DYN shares. Wall Street Zen cut Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Monday. Evercore set a $33.00 price objective on Dyne Therapeutics in a report on Friday, May 15th. Cantor Fitzgerald began coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They set an "overweight" rating on the stock. Finally, Royal Bank Of Canada raised their price objective on Dyne Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Thursday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $34.42.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source